

## 41<sup>st</sup> Volume Index / 41. Cilt Dizini SUBJECT INDEX 2024 – KONU DİZİNİ 2024

### 1. Acute Leukemia

Acute lymphoblastic leukemia/Akut lenfoblastik lösemi 125, 146  
 Acute myeloid leukemia/Akut myeloid lösemi 129, 192  
 Acute promyelocytic leukemia/Akut promiyelositik lösemi 1, 114, 198, 201  
 Allogeneic hematopoietic stem cell transplantation/Allojenik hematopoietik kök hücre transplantasyonu 9  
 Antimyeloma agents/Antimiyelom ajanlar 226  
 Antiviral prophylaxis/Antiviral profilaksi 9  
 B-cell acute lymphoblastic leukemia/B-hücre akut lenfoblastik lösemi 49  
 Basophilic maturation/Bazofilik olgunlaşma 114  
 Charges/Ücretlendirme 1  
 Child/Çocuk 146  
 Cleaved leukemic blast cells/Yarıklı lösemik blast hücreleri 192  
 Complications/Komplikasyonlar 1  
 Cytomegalovirus reactivation/Sitomegalovirüs reaktivasyonu 9  
 De novo pure erythroid leukemia/De novo saf eritroid lösemi 272  
 Diagnosis/Teşhis 114  
 Disseminated intravascular coagulation/Yaygın damar içi pıhtılaşma 1  
 DNA mismatch repair/DNA yanlış eşleşme tamiri 127  
 Donor selection/Donör seçimi 182  
 Essential thrombocythemia/Esansiyel trombositemi 125  
 Exome analysis/Egzom analizi 127  
 Flow cytometry/Akım sitometri 114  
 Four-way translocation/Dört-yol translokasyonu 129  
 Hematopoietic stem cell transplantation/Hematopoietik kök hücre nakli 182, 226  
 HSCT/HKHN 182  
 Humoral immune response/Hümmoral bağışıklık yanıtı 160  
 Immunoglobulins/İmmünoglobulinler 160  
 Immunomodulatory agents/İmmünomodülatör ajanlar 226  
 Immunophenotyping/İmmünotipleme 192  
 In-hospital mortality/Hastane içi mortalite 1  
 Infection/Enfeksiyon 160  
 Inotuzumab ozogamicin/İnotuzumab ozogamisin 203  
 JAK2V617F mutation/JAK2V617F mutasyonu 125  
 Length of stay/Kalış süresi 1  
 Letermovir/Letermovir 9  
 Leukemia/Lösemi 127  
 Leukemic blasts/Lösemik blastlar 272  
 Lymphoma/Lenfoma 127  
 MAPK1::BCR/MAPK1::BCR 198  
 Mixed-phenotype acute leukemia/Mikst fenotip akut lösemi 203  
 Mutation/Mutasyon 201  
 Pediatric leukemia/Pediyatrik lösemi 160  
 Peripheral hemophagocytosis/Çevresel hemofagositoz 272

Philadelphia chromosome-positive/Philadelphia kromozom pozitif 125  
 PML::RARA/PML::RARA 198, 201  
 Primary plasma cell leukemia/Primer plazma hücreli lösemi 226  
 Prognosis/Prognoz 49  
 Prognostic factors/Prognostik faktörler 146  
 Proteasome inhibitors/Proteazom inhibitörleri 226  
 Rare gene/Nadir gen 49  
 Relapse/Nüks 201  
 RNA sequencing/RNA dizileme 198  
 RUNX1::RUNX1T1/RUNX1::RUNX1T1 129  
 Standardized protocols/Standartlaştırılmış protokoller 182  
 Survey/Anket 182  
 Survival/Sağkalım 146  
 t(8;21)/t(8;21) 129  
 t(9;22)(q34;q11)/t(9;22)(q34;q11) 198  
 Targeted therapy/Hedefe yönelik tedavi 203  
 TLS::ERG fusion gene/TLS::ERG füzyon geni 192  
 Urine specimen/İdrar örneği 272  
 Vacuolation/Vakuolleşme 192

### 2. Anemia

Acute lymphoblastic leukemia/Akut lenfoblastik lösemi 290  
 ADA2 gene/ADA2 geni 133  
 Autoinflammatory disease/Otoenflamatuvar hastalık 133  
 Chest/Göğüs 189  
 Clonality/Klonalite 280  
 Computed tomography/Bilgisayarlı tomografi 189  
 Congenital methemoglobinemia/Doğuştan methemoglobinemi 282  
 Corticosteroids/Kortikosteroidler 210  
 CYB5R/CYB5R 282  
 Daratumumab/Daratumumab 290  
 De novo pure erythroid leukemia/De novo saf eritroid lösemi 272  
 Deficiency of adenosine deaminase 2/Adenozin deaminaz 2 eksikliği 133  
 Direct antiglobulin test/Direkt antiglobulin testi 210  
 Eltrombopag/Eltrombopag 290  
 Eosinophils/Eozinofiller 280  
 Epstein-Barr virus/Epstein-Barr virüsü 210  
 Extramedullary hematopoiesis/Ekstramedüller hematopoiezis 189  
 Immunodeficiency/İmmün yetmezlik 133  
 Immunoglobulin G autoantibody/İmmünoglobulin G otoantikoru 210  
 Leukemic blasts/Lösemik blastlar 272  
 Peripheral hemophagocytosis/Çevresel hemofagositoz 272  
 Polycythemia/Polisitemi 282  
 Pure red cell aplasia/Saf eritroid hücre aplazisi 290  
 Pure red cell aplasia/Saf kırmızı hücre aplazisi 133  
 Saturation gap/Satürasyon farkı 282

Sickle cell disease/Orak hücre anemisi 189  
 Spleen/Dalak 280  
 Urine specimen/İdrar örneği 272  
 Warm autoimmune hemolytic anemia/Sıcak otoimmün hemolitik anemi 210

### 3. Bleeding Disorders

Acquired hemophilia A/Edinsel hemofili A 264  
 Acute promyelocytic leukemia/Akut promiyelositik lösemi 1  
 Adult primary immune thrombocytopenia/Erişkin primer immün trombositopeni 97, 141  
 Bleeding/Kanama 264  
 Bypassing agents/Bypass ajanları 264  
 Charges/Ücretlendirme 1  
 Chemical synovectomy/Kimyasal sinovektomi 64  
 Complications/Komplikasyonlar 1  
 Delphi method/Delphi metodu 97, 141  
 Disseminated intravascular coagulation/Yaygın damar içi pıhtılaşma 1  
 Efficacy/Etkililik 256  
 Emicizumab/Emisizumab 256  
 Factor VIII inhibitors/Faktör VIII inhibitörleri 264  
 Factor XII deficiency/Faktör XII eksikliği 67  
 Genetic mutation/Genetik mutasyon 67  
 Hemophilia A/Hemofili A 256  
 Hemophilia/Hemofili 64  
 In-hospital mortality/Hastane içi mortalite 1  
 Inhibitor eradication/İnhibitör eradikasyonu 264  
 Length of stay/Kalış süresi 1  
 Management/Hastalık yönetimi 97, 141  
 Novel mutation/Yeni mutasyon 67  
 Rifampicin/Rifampisin 64  
 Safety/Güvenlilik 256  
 Special considerations/Özel durumlar 141  
 Toxic hepatitis/Toksik hepatit 64

### 4. Chronic Leukemia

ACEF score/ACEF skoru 91  
 Acute lymphoblastic leukemia/Akut lenfoblastik lösemi 125  
 Arrhythmia/Aritmi 91  
 Arterial stenosis/Arteriyel darlık 60  
 B-cell neoplasms/B-hücreli neoplaziler 56  
 Chronic lymphocytic leukemia/Kronik lenfositik lösemi 56, 58, 91  
 Chronic myeloid leukemia/Kronik miyeloid lösemi 60, 116, 287  
 Circulating monocytes/Dolaşımdaki monositler 54  
 CML diagnostic techniques/KML tanısal teknikler 287  
 CML management/KML yönetimi 287  
 CML therapies in Pakistan/Pakistan'da KML tedavisi 287  
 Cytoreductive treatment/Sitoredüktif tedavi 246  
 Dasatinib/Dasatinib 116  
 Essential thrombocythemia/Esansiyel trombositemi 125  
 Flow cytometric analysis/Akım sitometri analizi 54

Hypereosinophilia/Hipereozinofili 277  
 Hypopigmentation/Hipopigmentasyon 116  
 Ibrutinib-associated vasculitis/İbrutinib ilişkili vaskülit 58  
 Ibrutinib/İbrutinib 56, 58, 91  
 Interferon/İnterferon 246  
 JAK2V617F mutation/JAK2V617F mutasyonu 125  
 JAK2V617F/JAK2V617 175  
 Leukocytoclastic vasculitis/Lökositoklastik vaskülit 58  
 Lymphomas/Lenfomalar 292  
 Megakaryocytes/Megakaryositler 56  
 MPN-SAF TSS/MPN-SAF TSS 175  
 Myelodysplastic syndrome/Miyelodisplastik sendrom 277  
 Myelofibrosis/Miyelofibrozis 277  
 Myeloproliferative neoplasm/Miyeloproliferatif neoplazi 277  
 Myeloproliferative neoplasms/Miyeloproliferatif neoplaziler 175  
 Nilotinib/Nilotinib 60  
 Non-Hodgkin lymphoma/Hodgkin dışı lenfomalar 292  
 Phagocytosis/Fagositoz 54  
 Pharmacotherapeutics/Farnakoterapotikler 292  
 Philadelphia chromosome-negative myeloproliferative neoplasm/Philadelphia-negatif kronik miyeloproliferatif neoplazi 246  
 Philadelphia chromosome-positive/Philadelphia kromozom pozitif 125  
 Secondary solid cancers/Sekonder solid kanser 246  
 Small-cell variant/Küçük hücreli varyant 54  
 STAT5BN642H/STAT5BN642H 277  
 Symptom burden/Semptom yükü 175  
 T-cell neoplasms/T-hücreli neoplaziler 292  
 T-cell prolymphocytic leukemia/T-hücreli prolenfositik lösemi 54  
 Thrombocytopenia/Trombositopeni 56  
 Thrombosis/Tromboz 175  
 TKI resistance/TKI direnci 287  
 Tyrosine kinase inhibitors/Tirozin kinaz inhibitörleri 116

### 5. Coagulation

ACEF score/ACEF skoru 91  
 Acquired hemophilia A/Edinsel hemofili A 264  
 Acute promyelocytic leukemia/Akut promiyelositik lösemi 1  
 Allogeneic hematopoietic stem cell transplantation/Allojenik hematopoietik kök hücre transplantasyonu 9  
 Antiphospholipid antibodies/Antifosfolipid antikorları 37  
 Antiphospholipid antibody/Antifosfolipid antikor 122  
 Antiphospholipid syndrome/Antifosfolipid sendromu 37, 122  
 Antiplatelet therapy/Antitrombosit tedavi 105  
 Antiviral prophylaxis/Antiviral profilaksi 9  
 Arrhythmia/Aritmi 91  
 Arterial stenosis/Arteriyel darlık 60  
 Atherosclerosis/Aterosklerozis 167  
 Bleeding/Kanama 264  
 Bypassing agents/Bypass ajanları 264  
 Cardiovascular disorder/Kardiyovasküler hastalıklar 105  
 Charges/Ücretlendirme 1

- Chemical synovectomy/Kimyasal sinovektomi 64
- Chronic lymphocytic leukemia/Kronik lenfositik lösemi 91
- Chronic myeloid leukemia/Kronik miyeloid lösemi 60
- Classification criteria/Sınıflandırma kriterleri 37
- Clonal hematopoiesis/Klonal hematopoiezis 167
- Cold agglutinin disease/Soğuk agglutinin hastalığı 208
- Complications/Komplikasyonlar 1
- Cytomegalovirus reactivation/Sitomegalovirüs reaktivasyonu 9
- Disseminated intravascular coagulation/Yaygın damar içi pıhtılaşma 1
- Efficacy/Etkinlilik 256
- Emicizumab/Emisizumab 256
- Factor VIII inhibitors/Faktör VIII inhibitörleri 264
- Factor XII deficiency/Faktör XII eksikliği 67
- Genetic mutation/Genetik mutasyon 67
- Hemophilia A/Hemofili A 256
- Hemophilia/Hemofili 64
- Ibrutinib/İbrutinib 91
- Immunoglobulin/İmmünglobulin 122
- In-hospital mortality/Hastane içi mortalite 1
- Inhibitor eradication/İnhibitör eradikasyonu 264
- JAK2V617F mutation/JAK2V617F mutasyonu 167
- JAK2V617F/JAK2V617 175
- Length of stay/Kalış süresi 1
- Letermovir/Letermovir 9
- Lumiaggregometry/Lumiaggregometri 305
- MPN-SAF TSS/MPN-SAF TSS 175
- Myeloproliferative neoplasms/Miyeloproliferatif neoplaziler 167, 175
- Nilotinib/Nilotinib 60
- Novel mutation/Yeni mutasyon 67
- Obinutuzumab/Obinutuzumab 208
- Platelet Function Analyzer-100/Platelet Function Analyzer-100 105
- Rifampicin/Rifampisin 64
- Safety/Güvenlilik 256
- Symptom burden/Semptom yükü 175
- Thrombosis/Tromboz 175
- Toxic hepatitis/Toksik hepatit 64
- Treatment/Tedavi 208
- 6. Hematological Malignancies**
- 1q21 gain/amplification/1q21 kazanımı/amplifikasyonu 83
- ACEF score/ACEF skoru 91
- Acquired neutropenia/Kazanılmış nötropeni 44
- Acute lymphoblastic leukemia/Akut lenfoblastik lösemi 125, 146
- Acute myeloid leukemia/Akut miyeloid lösemi 129, 192
- Acute promyelocytic leukemia/Akut promiyelositik lösemi 1, 114, 198, 201
- Amyloidosis/Amiloidoz 274
- Antimyeloma agents/Antimiyelom ajanlar 226
- Arrhythmia/Aritmi 91
- Arterial stenosis/Arteriyel darlık 208
- Autophagosome/Otofagozom 16
- Autophagy/Otofaji 16
- B-cell acute lymphoblastic leukemia/B-hücre akut lenfoblastik lösemi 49
- B-cell neoplasms/B-hücreli neoplaziler 56
- Basophilic maturation/Bazofilik olgunlaşma 114
- Calprotectin/Kalprotektin 63
- CALR mutation/CALR mutasyonu 26
- CD117/CD117 236
- CD56/CD56 236
- Charges/Ücretlendirme 1
- Child/Çocuk 146
- Chronic lymphocytic leukemia/Kronik lenfositik lösemi 56, 58, 91
- Chronic myeloid leukemia/Kronik miyeloid lösemi 60, 287
- Circulating monocytes/Dolaşımdaki monositler 54
- Cleaved leukemic blast cells/Yarıklı lösemik blast hücreleri 192
- CML diagnostic techniques/KML tanısal teknikler 287
- CML management/KML yönetimi 287
- CML therapies in Pakistan/Pakistan'da KML tedavisi 287
- Cold agglutinin disease/Soğuk agglutinin hastalığı 208
- Complications/Komplikasyonlar 1
- Computed tomography/Bilgisayarlı tomografi 274
- Cytogenetic abnormalities/Sitogenetik anormallikler 236
- Cytoreductive treatment/Sitoredüktif tedavi 246
- De novo pure erythroid leukemia/De novo saf eritroid lösemi 272
- Developing countries/Gelişmekte olan ülkeler 212
- Diagnosis/Teşhis 114
- Discontinuation/Sonlandırma 284
- Disseminated intravascular coagulation/Yaygın damar içi pıhtılaşma 1
- DNA mismatch repair/DNA yanlış eşleşme tamiri 127
- Donor selection/Donör seçimi 182
- Dyspnea/Dispne 274
- Essential thrombocythemia/Esansiyel trombositemi 26, 125
- Exome analysis/Egzom analizi 127
- Flow cytometric analysis/Akım sitometri analizi 54
- Flow cytometry/Akım sitometri 114
- Follicular lymphoma/Foliküler lenfoma 69
- Four-way translocation/Dört-yol translokasyonu 129
- Gliflozins/Gliflozinler 131
- Hematological neoplasms/Hematolojik neoplazmlar 212
- Hematopoietic stem cell transplantation/Hematopoietik kök hücre nakli 182, 212, 226
- HMG1/HMG1 83
- HSCT/HKHN 182
- Humoral immune response/Hümorale bağışıklık yanıtı 160
- Hypereosinophilia/Hipereozinofili 277
- Hypogammaglobulinemia/Hipogamaglobulinemi 51
- Ibrutinib-associated vasculitis/İbrutinib ilişkili vaskülit 58
- Ibrutinib/İbrutinib 56, 58, 91
- Idiopathic multicentric Castleman disease/İdiyopatik multisentrik Castleman hastalığı 62, 284

- Immunoglobulin replacement therapy/İmmünoglobulin replasman tedavisi 51
- Immunoglobulins/İmmünoglobulinler 160
- Immunology/İmmunoloji 42
- Immunomodulatory agents/İmmünomodülatör ajanlar 226
- Immunophenotyping/İmmünotipleme 192
- In-hospital mortality/Hastane içi mortalite 1
- Infection/Enfeksiyon 160
- Inotuzumab ozogamicin/İnotuzumab ozogamisın 203
- Interferon/İnterferon 246
- JAK2V617F mutation/JAK2V617F mutasyonu 26, 125
- JAK2V617F/JAK2V617 175
- Janus kinase inhibitor/Janus kinaz inhibitörü 62
- Lacrimal gland/Lakrimal bez 191
- Length of stay/Kalış süresi 1
- Leukemia/Lösemi 127
- Leukemic blasts/Lösemik blastlar 272
- Leukocytoclastic vasculitis/Lökositoklastik vaskülit 58
- Lung/Akciğer 274
- Lymphoma/Lenfoma 44, 127
- Lymphomas/Lenfomalar 292
- Lytic bone lesion/Litik kemik lezyonu 205
- MAPK1::BCR/MAPK1::BCR 198
- Marginal zone lymphoma/Marjinal zon lenfoma 191
- Marrow/Kemik iliği 42
- Megakaryocytes/Megakaryositler 56
- Missing bone/Eksik kemik 205
- Mixed-phenotype acute leukemia/Mikst fenotip akut lösemi 203
- MPN-SAF TSS/MPN-SAF TSS 175
- Multiple myeloma/Çoklu miyelom 16, 51, 205, 236, 274
- Mutation/Mutasyon 201
- Myelodysplastic syndrome/Miyelodisplastik sendrom 277
- Myelofibrosis/Miyelofibrozis 277
- Myeloma and other plasma cell dyscrasias/Myelom ve diğer plazma hücre diskrazileri 42
- Myeloproliferative neoplasm/Miyeloproliferatif neoplazi 277
- Myeloproliferative neoplasm/Miyeloproliferatif neoplazm 26
- Myeloproliferative neoplasms/Miyeloproliferatif neoplaziler 131, 175
- Myxoma virus/Miksoma virüsü 16
- Neoplasia/Neoplazi 42
- Nilotinib/Nilotinib 60
- Non-Hodgkin lymphoma/Hodgkin dışı lenfomalar 292
- Obinutuzumab/Obinutuzumab 208
- Pediatric leukemia/Pediyatrik lösemi 160
- Peripheral hemophagocytosis/Çevresel hemofagositoz 272
- Phagocytosis/Fagositoz 54
- Pharmacotherapeutics/Farnakoterapotikler 292
- Philadelphia chromosome-negative myeloproliferative neoplasm/Philadelphia-negatif kronik miyeloproliferatif neoplazi 246
- Philadelphia chromosome-positive/Philadelphia kromozom pozitif 125
- Plasmacytoma/Plazmasitom 205
- PML::RARA/PML::RARA 198, 201
- Primary lymphoma/Primer lenfoma 191
- Primary plasma cell leukemia/Primer plazma hücreli lösemi 226
- Prognosis/Prognoz 49
- Prognostic factors/Prognostik faktörler 146
- Proteasome inhibitors/Proteazom inhibitörleri 226
- Rare gene/Nadir gen 49
- Real-world evidence/Gerçek dünyada verileri 212
- Relapse/Nüks 201, 284
- Resource limitations/Sınırlı kaynaklar 212
- Review/Derleme 69
- RNA sequencing/RNA dizileme 198
- RUNX1::RUNX1T1/RUNX1::RUNX1T1 129
- Ruxolitinib/Ruxolitinib 62
- S100A6/S100A6 83
- S100A8/9/S100A8/9 83
- Secondary solid cancers/Sekonder solid kanser 246
- Siltuximab/Siltuksimab 284
- Small-cell variant/Küçük hücreli varyant 54
- Standardized protocols/Standartlaştırılmış protokoller 182
- STAT5BN642H/STAT5BN642H 277
- Survey/Anket 182
- Survival/Sağkalım 146, 236
- Symptom burden/Semptom yükü 175
- T-cell neoplasms/T-hücreli neoplaziler 292
- T-cell neoplasms/T-hücreli neoplazmlar 44
- T-cell prolymphocytic leukemia/T-hücreli prolenfositik lösemi 54
- t(8;21)/t(8;21) 129
- t(9;22)(q34;q11)/t(9;22)(q34;q11) 198
- Targeted therapy/Hedefe yönelik tedavi 203
- Thrombocytopenia/Trombositopeni 56
- Thrombosis/Tromboz 131, 175
- TKI resistance/TKI direnci 287
- TLS::ERG fusion gene/TLS::ERG füzyon geni 192
- Treatment management/Tedavi yönetimi 69
- Treatment outcome/Tedavi sonucu 212
- Treatment/Tedavi 62, 208
- Ulceronecrotic dyschromic plaques/Ülseronekrotik diskromik plaklar 44
- Urine specimen/İdrar örneği 272
- Vacuolation/Vakuolleşme 192

## 7. Immunohematology

- 1q21 gain/amplification/1q21 kazanımı/amplifikasyonu 83
- Acute promyelocytic leukemia/Akut promiyelositik lösemi 114
- ADA2 gene/ADA2 geni 133
- Antimyeloma agents/Antimiyelom ajanlar 226
- Antiphospholipid antibodies/Antifosfolipid antikorları 37
- Antiphospholipid antibody/Antifosfolipid antikoru 122
- Antiphospholipid syndrome/Antifosfolipid sendromu 37, 122
- Antiplatelet therapy/Antitrombosit tedavi 105

Autoinflammatory disease/Otoenflamatuvar hastalık 133  
 Basophilic maturation/Bazofilik olgunlaşma 114  
 Calprotectin/Kalprotektin 83  
 Cardiovascular disorder/Kardiyovasküler hastalıklar 105  
 CD117/CD117 236  
 CD56/CD56 236  
 Circulating monocytes/Dolaşımdaki monositler 54  
 Classification criteria/Sınıflandırma kriterleri 37  
 Corticosteroids/Kortikosteroidler 210  
 Cytogenetic abnormalities/Sitogenetik anormallikler 236  
 Deficiency of adenosine deaminase 2/Adenozin deaminaz 2 eksikliği 133  
 Developing countries/Gelişmekte olan ülkeler 212  
 Diagnosis/Teşhis 114  
 Direct antiglobulin test/Direkt antiglobulin testi 210  
 Discontinuation/Sonlandırma 284  
 Epstein-Barr virus/Epstein-Barr virüsü 210  
 Flow cytometric analysis/Akım sitometri analizi 54  
 Flow cytometry/Akım sitometri 114  
 Hematological neoplasms/Hematolojik neoplazmlar 212  
 Hematopoietic stem cell transplantation/Hematopoietik kök hücre nakli 212, 226  
 HMG1/HMG1 83  
 Humoral immune response/Hümmoral bağışıklık yanıtı 160  
 Idiopathic multicentric Castleman disease/İdiyopatik multisentrik Castleman hastalığı 62, 284  
 Immunodeficiency/İmmün yetmezlik 133  
 Immunoglobulin G autoantibody/İmmünoglobulin G otoantikoru 210  
 Immunoglobulin/İmmünoglobulin 122  
 Immunoglobulins/İmmünoglobulinler 160  
 Immunomodulatory agents/İmmünomodülatör ajanlar 226  
 Infection/Enfeksiyon 160  
 Inotuzumab ozogamicin/İnotuzumab ozogamisın 203  
 Janus kinase inhibitor/Janus kinaz inhibitörü 62  
 Lumiaggregometry/Lumiaggregometri 105  
 Mixed-phenotype acute leukemia/Mikst fenotip akut lösemi 203  
 Multiple myeloma/Multipl miyelom 236  
 Pediatric leukemia/Pediyatrik lösemi 160  
 Phagocytosis/Fagositoz 54  
 Platelet Function Analyzer-100/Platelet Function Analyzer-100 105  
 Primary plasma cell leukemia/Primer plazma hücreli lösemi 226  
 Proteasome inhibitors/Proteazom inhibitörleri 226  
 Pure red cell aplasia/Saf kırmızı hücre aplazisi 133  
 Real-world evidence/Gerçek dünyada verileri 212  
 Relapse/Nüks 284  
 Resource limitations/Sınırlı kaynaklar 212  
 Ruxolitinib/Ruxolitinib 62  
 S100A6/S100A6 83  
 S100A8/9/S100A8/9 83  
 Small-cell variant/Küçük hücreli varyant 54  
 Survival/Sağkalım 236

T-cell prolymphocytic leukemia/T-hücreli prolenfositik lösemi 54  
 Targeted therapy/Hedefe yönelik tedavi 203  
 Treatment outcome/Tedavi sonucu 212  
 Treatment/Tedavi 62  
 Warm autoimmune hemolytic anemia/Sıcak otoimmün hemolitik anemi 210

## 8. Infection Disorders

Acute lymphoblastic leukemia/Akut lenfoblastik lösemi 146  
 Allogeneic hematopoietic stem cell transplantation/Allojenik hematopoietik kök hücre transplantasyonu 9  
 Antiviral prophylaxis/Antiviral profilaksi 9  
 Autophagosome/Otofagozom 16  
 Autophagy/Otofaji 16  
 Bone marrow/Kemik iliği 119  
 Child/Çocuk 146  
 Clonality/Klonalite 280  
 Corticosteroids/Kortikosteroidler 210  
 Cytomegalovirus reactivation/Sitomegalovirüs reaktivasyonu 9  
 Direct antiglobulin test/Direkt antiglobulin testi 210  
 Eosinophils/Eozinofiller 280  
 Epstein-Barr virus/Epstein-Barr virüsü 210  
 Humoral immune response/Hümmoral bağışıklık yanıtı 160  
 Hypogammaglobulinemia/Hipogamaglobulinemi 51  
 Immunoglobulin G autoantibody/İmmünoglobulin G otoantikoru 210  
 Immunoglobulin replacement therapy/İmmünoglobulin replasman tedavisi 51  
 Immunoglobulins/İmmünoglobulinler 160  
 Infection/Enfeksiyon 160  
*Leishmania donovani* amastigotes/*Leishmania donovani* amastigotları 119  
 Letermovir/Letermovir 9  
 Multiple myeloma/Multipl miyelom 16, 51  
 Myxoma virus/Miksoma virüsü 16  
 Pediatric leukemia/Pediyatrik lösemi 160  
 Prognostic factors/Prognostik faktörler 146  
 Spleen/Dalak 280  
 Survival/Sağkalım 146  
 Visceral leishmaniasis/Visseral leishmaniasis 119  
 Warm autoimmune hemolytic anemia/Sıcak otoimmün hemolitik anemi 210

## 9. Lymphoma

Acquired neutropenia/Kazanılmış nötropeni 44  
 Developing countries/Gelişmekte olan ülkeler 212  
 Follicular lymphoma/Foliküler lenfoma 69  
 Hematological neoplasms/Hematolojik neoplazmlar 212  
 Hematopoietic stem cell transplantation/Hematopoietik kök hücre nakli 212  
 Lacrimal gland/Lakrimal bez 191  
 Lymphoma/Lenfoma 44  
 Marginal zone lymphoma/Marjinal zon lenfoma 191



Primary lymphoma/Primer lenfoma 191  
 Real-world evidence/Gerçek dünyada verileri 212  
 Resource limitations/Sınırlı kaynaklar 212  
 Review/Derleme 69  
 T-cell neoplasms/T-hücreli neoplazmlar 44  
 Treatment management/Tedavi yönetimi 69  
 Treatment outcome/Tedavi sonucu 212  
 Ulceronecrotic dyschromic plaques/Ülseronekrotik diskromik plaklar 44

## 10. Molecular Hematology

Acute myeloid leukemia/Akut myeloid lösemi 129, 192  
 Acute promyelocytic leukemia/Akut promiyelositik lösemi 198, 201  
 ADA2 gene/ADA2 geni 133  
 Atherosclerosis/Aterosklerozis 167  
 Autoinflammatory disease/Otoenflamatuvar hastalık 133  
 B-cell acute lymphoblastic leukemia/B-hücre akut lenfoblastik lösemi 49  
 Cleaved leukemic blast cells/Yarıklı lösemik blast hücreleri 192  
 Clonal hematopoiesis/Klonal hematopoiezis 167  
 Congenital methemoglobinemia/Doğuştan methemoglobinemi 282  
 CYB5R/CYB5R 282  
 Deficiency of adenosine deaminase 2/Adenozin deaminaz 2 eksikliği 133  
 DNA mismatch repair/DNA yanlış eşleşme tamiri 127  
 Exome analysis/Egzom analizi 127  
 Factor XII deficiency/Faktör XII eksikliği 67  
 Follicular lymphoma/Foliküler lenfoma 69  
 Four-way translocation/Dört-yol translokasyonu 129  
 Genetic mutation/Genetik mutasyon 67  
 Hypereosinophilia/Hipereozinofili 277  
 Immunodeficiency/İmmün yetmezlik 133  
 Immunophenotyping/İmmünofenotipleme 192  
 JAK2V617F mutation/JAK2V617F mutasyonu 167  
 JAK2V617F/JAK2V617 175  
 Leukemia/Lösemi 127  
 Lymphoma/Lenfoma 127  
 MAPK1::BCR/MAPK1::BCR 198  
 MPN-SAF TSS/MPN-SAF TSS 175  
 Mutation/Mutasyon 201  
 Myelodysplastic syndrome/Miyelodisplastik sendrom 277  
 Myelofibrosis/Miyelofibrozis 277  
 Myeloproliferative neoplasm/Miyeloproliferatif neoplazi 277  
 Myeloproliferative neoplasms/Miyeloproliferatif neoplaziler 167, 175  
 Novel mutation/Yeni mutasyon 67  
 PML::RARA/PML::RARA 198, 201  
 Polycythemia/Polisitemi 282  
 Prognosis/Prognoz 49  
 Pure red cell aplasia/Saf kırmızı hücre aplazisi 133  
 Rare gene/Nadir gen 49  
 Relapse/Nüks 201

Review/Derleme 69  
 RNA sequencing/RNA dizileme 198  
 RUNX1::RUNX1T1/RUNX1::RUNX1T1 129  
 Saturation gap/Satürasyon farkı 282  
 STAT5BN642H/STAT5BN642H 277  
 Symptom burden/Semptom yükü 175  
 t(8;21)/t(8;21) 129  
 t(9;22)(q34;q11)/t(9;22)(q34;q11) 198  
 Thrombosis/Tromboz 175  
 TLS::ERG fusion gene/TLS::ERG füzyon geni 192  
 Treatment management/Tedavi yönetimi 69  
 Vacuolation/Vakuolleşme 192

## 11. Multiple Myeloma

1q21 gain/amplification/1q21 kazanımı/amplifikasyonu 83  
 Amyloidosis/Amiloidoz 274  
 Antimyeloma agents/Antimiyelom ajanlar 226  
 Autophagosome/Otofagozom 16  
 Autophagy/Otofaji 16  
 Calprotectin/Kalprotektin 83  
 CD117/CD117 236  
 CD56/CD56 236  
 Cold agglutinin disease/Soğuk agglutinin hastalığı 208  
 Computed tomography/Bilgisayarlı tomografi 274  
 Cytogenetic abnormalities/Sitogenetik anormallikler 236  
 Dyspnea/Dispne 274  
 Hematopoietic stem cell transplantation/Hematopoietik kök hücre nakli 226  
 HMGN1/HMGN1 83  
 Hypogammaglobulinemia/Hipogamaglobulinemi 51  
 Immunoglobulin replacement therapy/İmmünoglobulin replasman tedavisi 51  
 Immunology/İmmunoloji 42  
 Immunomodulatory agents/İmmünomodülatör ajanlar 226  
 Lung/Akciğer 274  
 Lytic bone lesion/Litik kemik lezyonu 205  
 Marrow/Kemik iliği 42  
 Missing bone/Eksik kemik 205  
 Multiple myeloma/Multipl miyelom 16, 51, 205, 236, 274  
 Myeloma and other plasma cell dyscrasias/Myelom ve diğer plazma hücre diskrazileri 42  
 Myxoma virus/Miksoma virüsü 16  
 Neoplasia/Neoplazi 42  
 Obinutuzumab/Obinutuzumab 208  
 Plasmacytoma/Plazmasitom 205  
 Primary plasma cell leukemia/Primer plazma hücreli lösemi 226  
 Proteasome inhibitors/Proteazom inhibitörleri 226  
 S100A6/S100A6 83  
 S100A8/9/S100A8/9 83  
 Survival/Sağkalım 236  
 Treatment/Tedavi 208

**12. Myeloproliferative Disorders**

Acute lymphoblastic leukemia/Akut lenfoblastik lösemi 125  
 Arterial stenosis/Arteriyel darlık 60  
 Atherosclerosis/Aterosklerozis 167  
 CALR mutation/CALR mutasyonu 26  
 Chronic myeloid leukemia/Kronik miyeloid lösemi 60, 116, 287  
 Clonal hematopoiesis/Klonal hematopoiezis 167  
 CML diagnostic techniques/KML tanısal teknikler 287  
 CML management/KML yönetimi 287  
 CML therapies in Pakistan/Pakistan'da KML tedavisi 287  
 Cytoreductive treatment/Sitoredüktif tedavi 246  
 Dasatinib/Dasatinib 116  
 Essential thrombocythemia/Esansiyel trombositemi 26, 125  
 Gliflozins/Gliflozinler 131  
 Hypopigmentation/Hipopigmentasyon 116  
 Interferon/İnterferon 246  
 JAK2V617F mutation/JAK2V617F mutasyonu 26, 125, 167  
 JAK2V617F/JAK2V617 175  
 MPN-SAF TSS/MPN-SAF TSS 175  
 Myeloproliferative neoplasm/Miyeloproliferatif neoplazm 26  
 Myeloproliferative neoplasms/Miyeloproliferatif neoplaziler 167, 175  
 Myeloproliferative neoplasms/Myeloproliferatif neoplaziler 131  
 Nilotinib/Nilotinib 60  
 Philadelphia chromosome-negative myeloproliferative neoplasm/  
 Philadelphia-negatif kronik miyeloproliferatif neoplazi 246  
 Philadelphia chromosome-positive/Philadelphia kromozom pozitif 125  
 Secondary solid cancers/Sekonder solid kanser 246  
 Symptom burden/Semptom yükü 175  
 Thrombosis/Tromboz 131, 175  
 TKI resistance/TKI direnci 287  
 Tyrosine kinase inhibitors/Tirozin kinaz inhibitörleri 116

**13. Stem Cell Transplantation**

Acute lymphoblastic leukemia/Akut lenfoblastik lösemi 290  
 Allogeneic hematopoietic stem cell transplantation/Allojenik  
 hematopoietik kök hücre transplantasyonu 9  
 Antiviral prophylaxis/Antiviral profilaksi 9  
 Cytomegalovirus reactivation/Sitomegalovirüs reaktivasyonu 9  
 Daratumumab/Daratumumab 290  
 Donor selection/Donör seçimi 182  
 Eltrombopag/Eltrombopag 290  
 Hematopoietic stem cell transplantation/Hematopoietik kök hücre  
 nakli 182  
 HSCT/HKHN 182  
 Letermovir/Letermovir 9  
 Pure red cell aplasia/Saf eritroid hücre aplazisi 290  
 Standardized protocols/Standartlaştırılmış protokoller 182  
 Survey/Anket 182

**14. Thrombosis**

ACEF score/ACEF skoru 91  
 Acute promyelocytic leukemia/Akut promiyelositik lösemi 1

ADA2 gene/ADA2 geni 133  
 Antiphospholipid antibodies/Antifosfolipid antikorları 37  
 Antiphospholipid antibody/Antifosfolipid antikor 122  
 Antiphospholipid syndrome/Antifosfolipid sendromu 37, 122  
 Antiplatelet therapy/Antitrombosit tedavi 105  
 Arrhythmia/Aritmi 91  
 Arterial stenosis/Arteriyel darlık 60  
 Atherosclerosis/Aterosklerozis 167  
 Autoinflammatory disease/Otoenflamatuvar hastalık 133  
 CALR mutation/CALR mutasyonu 26  
 Cardiovascular disorder/Kardiyovasküler hastalıklar 105  
 Charges/Ücretlendirme 1  
 Chronic lymphocytic leukemia/Kronik lenfositik lösemi 58, 91  
 Chronic myeloid leukemia/Kronik miyeloid lösemi 60  
 Classification criteria/Sınıflandırma kriterleri 37  
 Clonal hematopoiesis/Klonal hematopoiezis 167  
 Cold agglutinin disease/Soğuk agglutinin hastalığı 208  
 Complications/Komplikasyonlar 1  
 Deficiency of adenosine deaminase 2/Adenozin deaminaz 2 eksikliği  
 133  
 Disseminated intravascular coagulation/Yaygın damar içi pıhtılaşma 1  
 Essential thrombocythemia/Esansiyel trombositemi 26  
 Gliflozins/Gliflozinler 131  
 Ibrutinib-associated vasculitis/İbrutinib ilişkili vaskülit 58  
 Ibrutinib/İbrutinib 58, 91  
 Immunodeficiency/İmmün yetmezlik 133  
 Immunoglobulin/İmmünoglobulin 122  
 In-hospital mortality/Hastane içi mortalite 1  
 JAK2V617F mutation/JAK2V617F mutasyonu 26, 167  
 JAK2V617F/JAK2V617 175  
 Length of stay/Kalış süresi 1  
 Leukocytoclastic vasculitis/Lökositoklastik vaskülit 58  
 Lumiaggregometry/Lumiaggregometri 105  
 MPN-SAF TSS/MPN-SAF TSS 175  
 Myeloproliferative neoplasm/Miyeloproliferatif neoplazm 26  
 Myeloproliferative neoplasms/Miyeloproliferatif neoplaziler 167, 175,  
 131  
 Nilotinib/Nilotinib 60  
 Obinutuzumab/Obinutuzumab 208  
 Platelet Function Analyzer-100/Platelet Function Analyzer-100 105  
 Pure red cell aplasia/Saf kırmızı hücre aplazisi 133  
 Symptom burden/Semptom yükü 175  
 Thrombosis/Tromboz 131, 175  
 Treatment/Tedavi 208

**15. Thrombocytopenia**

Acute lymphoblastic leukemia/Akut lenfoblastik lösemi 290  
 ADA2 gene/ADA2 geni 133  
 Adult primary immune thrombocytopenia/Erişkin primer immün  
 trombositopeni 97, 141  
 Autoinflammatory disease/Otoenflamatuvar hastalık 133

- B-cell neoplasms/B-hücreli neoplaziler 56  
 Chronic lymphocytic leukemia/Kronik lenfositik lösemi 56  
 Daratumumab/Daratumumab 290  
 Deficiency of adenosine deaminase 2/Adenozin deaminaz 2 eksikliği 133  
 Delphi method/Delphi metodu 97, 141  
 Eltrombopag/Eltrombopag 290  
 Ibrutinib/Ibrutinib 56  
 Immunodeficiency/İmmün yetmezlik 133  
 Management/Hastalık yönetimi 97, 141  
 Megakaryocytes/Megakaryositler 56  
 Pure red cell aplasia/Saf eritroid hücre aplazisi 290  
 Pure red cell aplasia/Saf kırmızı hücre aplazisi 133  
 Special considerations/Özel durumlar 141  
 Thrombocytopenia/Trombositopeni 56
- 16. Other**
- Acquired hemophilia A/Edinsel hemofili A 264  
 Acquired neutropenia/Kazanılmış nötropeni 44  
 ADA2 gene/ADA2 geni 133  
 Autoinflammatory disease/Otoenflamatuvar hastalık 133  
 Bleeding/Kanama 264  
 Bone marrow/Kemik iliği 119  
 Bypassing agents/Bypass ajanları 264  
 Chemical synovectomy/Kimyasal sinovektomi 64  
 Chest/Göğüs 189  
 Chronic lymphocytic leukemia/Kronik lenfositik lösemi 58  
 Chronic myeloid leukemia/Kronik myeloid lösemi 116, 287  
 Clasmatosis/Klazmatoz 46  
 CML diagnostic techniques/KML tanısal teknikler 287  
 CML management/KML yönetimi 287  
 CML therapies in Pakistan/Pakistan'da KML tedavisi 287  
 Computed tomography/Bilgisayarlı tomografi 189  
 Congenital methemoglobinemia/Doğuştan methemoglobinemi 282  
 CYB5R/CYB5R 282  
 Cytoreductive treatment/Sitoredüktif tedavi 246  
 Dasatinib/Dasatinib 116  
 Deficiency of adenosine deaminase 2/Adenozin deaminaz 2 eksikliği 133  
 Discontinuation/Sonlandırma 284  
 Donor selection/Donör seçimi 182  
 Efficacy/Etkinlik 256  
 Emicizumab/Emisizumab 256  
 Epithelial cells/Epitelial hücreler 47  
 Extramedullary hematopoiesis/Ekstramedüller hematopoiezis 189  
 Factor VIII inhibitors/Faktör VIII inhibitörleri 264  
 Gliflozins/Gliflozinler 131  
 Hematopoietic stem cell transplantation/Hematopoietik kök hücre nakli 182  
 Hemophilia A/Hemofili A 256  
 Hemophilia/Hemofili 64  
 HSCT/HKHN 182  
 Hypopigmentation/Hipopigmentasyon 116  
 Ibrutinib-associated vasculitis/Ibrutinib ilişkili vaskülit 58  
 Ibrutinib/Ibrutinib 58  
 Idiopathic multicentric Castleman disease/İdiyopatik multisentrik Castleman hastalığı 62, 284  
 Immunodeficiency/İmmün yetmezlik 133  
 Inhibitor eradication/İnhibitör eradikasyonu 264  
 Interferon/İnterferon 246  
 Janus kinase inhibitor/Janus kinaz inhibitörü 62  
 Lacrimal gland/Lakrimal bez 191  
 Leishmania donovani amastigotes/Leishmania donovani amastigotları 119  
 Leukocytoclastic vasculitis/Lökositoklastik vaskülit 58  
 Lymphoma/Lenfoma 44  
 Lymphomas/Lenfomalar 292  
 Marginal zone lymphoma/Marjinal zon lenfoma 191  
 Myeloproliferative neoplasms/Myeloproliferatif neoplaziler 131  
 Non-Hodgkin lymphoma/Hodgkin dışı lenfomalar 292  
 Peripheral blood review/Çevresel kan değerlendirmesi 46  
 Peripheral blood smear/Periferik kan yayması 47  
 Pharmacotherapeutics/Farnakoterapotikler 292  
 Philadelphia chromosome-negative myeloproliferative neoplasm/Philadelphia-negatif kronik miyeloproliferatif neoplazi 246  
 Polycythemia/Polisitemi 282  
 Primary lymphoma/Primer lenfoma 191  
 Primary myelofibrosis/Primer miyelofibrozis 62  
 Pure red cell aplasia/Saf kırmızı hücre aplazisi 133  
 Relapse/Nüks 284  
 Rifampicin/Rifampisin 64  
 Ruxolitinib/Ruxolitinib 62  
 Safety/Güvenlilik 256  
 Saturation gap/Satürasyon farkı 282  
 Secondary solid cancers/Sekonder solid kanser 246  
 Sick cell disease/Orak hücre anemisi 189  
 Standardized protocols/Standartlaştırılmış protokoller 182  
 Survey/Anket 182  
 T-cell neoplasms/T-hücreli neoplaziler 292  
 T-cell neoplasms/T-hücreli neoplazmlar 44  
 Thrombosis/Tromboz 131  
 TKI resistance/TKI direnci 287  
 Toxic hepatitis/Toksik hepatit 64  
 Treatment/Tedavi 62  
 Tyrosine kinase inhibitors/Tirozin kinaz inhibitörleri 116  
 Ulceronecrotic dyschromic plaques/Ülseronekrotik diskromik plaklar 44  
 Vascular smooth muscle cells/Vasküler düz kas hücreleri 47  
 Visceral leishmaniasis/Visseral leishmaniasis 119



**17. Pathology**

- 1q21 gain/amplification/1q21 kazanımı/amplifikasyonu 83  
 Acquired neutropenia/Kazanılmış nötropeni 44  
 Acute lymphoblastic leukemia/Akut lenfoblastik lösemi 125, 146, 290  
 Acute myeloid leukemia/Akut myeloid lösemi 129, 192  
 Acute promyelocytic leukemia/Akut promiyelositik lösemi 114, 198, 201  
 Amyloidosis/Amiloidoz 274  
 Antimyeloma agents/Antimiyelom ajanlar 226  
 B-cell acute lymphoblastic leukemia/B-hücre akut lenfoblastik lösemi 49  
 Basophilic maturation/Bazofilik olgunlaşma 114  
 Bone marrow/Kemik iliği 119  
 Calprotectin/Kalprotektin 83  
 CD117/CD117 236  
 CD56/CD56 236  
 Chest/Göğüs 189  
 Child/Çocuk 146  
 Chronic lymphocytic leukemia/Kronik lenfositik lösemi 58  
 Circulating monocytes/Dolaşımdaki monositler 54  
 Clasmatozis/Klazmatoz 46  
 Cleaved leukemic blast cells/Yarıklı lösemik blast hücreleri 192  
 Clonality/Klonalite 280  
 Cold agglutinin disease/Soğuk agglutinin hastalığı 208  
 Computed tomography/Bilgisayarlı tomografi 189, 274  
 Cytogenetic abnormalities/Sitogenetik anormallikler 236  
 Cytoreductive treatment/Sitoredüktif tedavi 246  
 Daratumumab/Daratumumab 290  
 De novo pure erythroid leukemia/De novo saf eritroid lösemi 272  
 Developing countries/Gelişmekte olan ülkeler 212  
 Diagnosis/Teşhis 114  
 Discontinuation/Sonlandırma 284  
 DNA mismatch repair/DNA yanlış eşleşme tamiri 127  
 Dyspnea/Dispne 274  
 Eltrombopag/Eltrombopag 290  
 Eosinophils/Eozinofiller 280  
 Epithelial cells/Epitelial hücreler 47  
 Essential thrombocythemia/Esansiyel trombositemi 125  
 Exome analysis/Egzom analizi 127  
 Extramedullary hematopoiesis/Ekstramedüller hematopoiezis 189  
 Flow cytometric analysis/Akım sitometri analizi 54  
 Flow cytometry/Akım sitometri 114  
 Follicular lymphoma/Foliküler lenfoma 69  
 Four-way translocation/Dört-yol translokasyonu 129  
 Hematological neoplasms/Hematolojik neoplazmlar 212  
 Hematopoietic stem cell transplantation/Hematopoietik kök hücre nakli 212, 226  
 HMGN1/HMGN1 83  
 Humoral immune response/Hümmoral bağışıklık yanıtı 160  
 Hypereosinophilia/Hipereozinofili 277  
 Ibrutinib-associated vasculitis/Ibrutinib ilişkili vaskülit 58  
 Idiopathic multicentric Castleman disease/İdiyopatik multisentrik Castleman hastalığı 62, 284  
 Immunoglobulins/İmmünoglobulinler 160  
 Immunology/İmmunoloji 42  
 Immunomodulatory agents/İmmünomodülatör ajanlar 226  
 Immunophenotyping/İmmünofenotipleme 192  
 Infection/Enfeksiyon 160  
 Inotuzumab ozogamicin/İnotuzumab ozogamisin 203  
 Interferon/İnterferon 246  
 JAK2V617F mutation/JAK2V617F mutasyonu 125  
 JAK2V617F/JAK2V617 175  
 Janus kinase inhibitor/Janus kinaz inhibitörü 62  
 Lacrimal gland/Lakrimal bez 191  
 Leishmania donovani amastigotes/Leishmania donovani amastigotları 119  
 Leukemia/Lösemi 127  
 Leukemic blasts/Lösemik blastlar 272  
 Leukocytoclastic vasculitis/Lökositoklastik vaskülit 58  
 Lung/Akciğer 274  
 Lymphoma/Lenfoma 44, 127  
 Lymphomas/Lenfomalar 292  
 Lytic bone lesion/Litik kemik lezyonu 205  
 MAPK1::BCR/MAPK1::BCR 198  
 Marginal zone lymphoma/Marjinal zon lenfoma 191  
 Marrow/Kemik iliği 42  
 Missing bone/Eksik kemik 205  
 Mixed-phenotype acute leukemia/Mikst fenotip akut lösemi 203  
 MPN-SAF TSS/MPN-SAF TSS 175  
 Multiple myeloma/Multipl miyelom 205, 236, 274  
 Mutation/Mutasyon 201  
 Myelodysplastic syndrome/Miyelodisplastik sendrom 277  
 Myelofibrosis/Miyelofibrozis 277  
 Myeloma and other plasma cell dyscrasias/Myelom ve diğer plazma hücre diskrazileri 42  
 Myeloproliferative neoplasm/Miyeloproliferatif neoplazi 277  
 Myeloproliferative neoplasms/Miyeloproliferatif neoplaziler 175  
 Neoplasia/Neoplazi 42  
 Non-Hodgkin lymphoma/Hodgkin dışı lenfomalar 292  
 Obinutuzumab/Obinutuzumab 208  
 Pediatric leukemia/Pediyatrik lösemi 160  
 Peripheral blood review/Çevresel kan değerlendirmesi 46  
 Peripheral blood smear/Periferik kan yayması 47  
 Peripheral hemophagocytosis/Çevresel hemofagositoz 272  
 Phagocytosis/Fagositoz 54  
 Pharmacotherapeutics/Farnakoterapotikler 292  
 Philadelphia chromosome-negative myeloproliferative neoplasm/Philadelphia-negatif kronik miyeloproliferatif neoplazi 246  
 Philadelphia chromosome-positive/Philadelphia kromozom pozitif 125  
 Plasmacytoma/Plazmasitom 205  
 PML::RARA/PML::RARA 198, 201

Primary lymphoma/Primer lenfoma 191  
Primary myelofibrosis/Primer miyelofibrozis 46  
Primary plasma cell leukemia/Primer plazma hücreli lösemi 226  
Prognosis/Prognoz 49  
Prognostic factors/Prognostik faktörler 146  
Proteasome inhibitors/Proteazom inhibitörleri 226  
Pure red cell aplasia/Saf eritroid hücre aplazisi 290  
Rare gene/Nadir gen 49  
Real-world evidence/Gerçek dünyada verileri 212  
Relapse/Nüks 201, 284  
Resource limitations/Sınırlı kaynaklar 212  
Review/Derleme 69  
RNA sequencing/RNA dizileme 198  
*RUNX1::RUNX1T1/RUNX1::RUNX1T1* 129  
Ruxolitinib/Ruxolitinib 62  
S100A6/S100A6 83  
S100A8/9/S100A8/9 83  
Secondary solid cancers/Sekonder solid kanser 246  
Sickle cell disease/Orak hücre anemisi 189  
Small-cell variant/Küçük hücreli varyant 54  
Spleen/Dalak 280  
*STAT5BN642H/STAT5BN642H* 277  
Survival/Sağkalım 146, 236  
Symptom burden/Semptom yükü 175  
T-cell neoplasms/T-hücreli neoplaziler 292  
T-cell neoplasms/T-hücreli neoplazmlar 44  
T-cell prolymphocytic leukemia/T-hücreli prolenfositik lösemi 54  
t(8;21)/t(8;21) 129  
t(9;22)(q34;q11)/t(9;22)(q34;q11) 198  
Targeted therapy/Hedefe yönelik tedavi 203  
Thrombosis/Tromboz 175  
*TLS::ERG* fusion gene/*TLS::ERG* füzyon geni 192  
Treatment management/Tedavi yönetimi 69  
Treatment outcome/Tedavi sonucu 212  
Treatment/Tedavi 62, 208

Ulceronecrotic dyschromic plaques/Ülseronekrotik diskromik plaklar 44  
Urine specimen/İdrar örneği 272  
Vacuolation/Vakuolleşme 192  
Vascular smooth muscle cells/Vasküler düz kas hücreleri 47  
Visceral leishmaniasis/Visseral leishmaniasis 119

## 18. Autoimmune Disorders

Adult primary immune thrombocytopenia/Erişkin primer immün trombositopeni 97, 141  
Antiphospholipid antibodies/Antifosfolipid antikörleri 37  
Antiphospholipid antibody/Antifosfolipid antikoru 122  
Antiphospholipid syndrome/Antifosfolipid sendromu 37, 122  
Classification criteria/Sınıflandırma kriterleri 37  
Corticosteroids/Kortikosteroidler 210  
Delphi method/Delphi metodu 97, 141  
Direct antiglobulin test/Direkt antiglobulin testi 210  
Epstein-Barr virus/Epstein-Barr virüsü 210  
Immunoglobulin G autoantibody/İmmünoglobulin G otoantikoru 210  
Immunoglobulin/İmmünoglobulin 122  
Management/Hastalık yönetimi 97, 141  
Special considerations/Özel durumlar 141  
Warm autoimmune hemolytic anemia/Sıcak otoimmün hemolitik anemi 210

## 19. Transfusion

Hypogammaglobulinemia/Hipogamaglobulinemi 51  
Immunoglobulin replacement therapy/İmmünoglobulin replasman tedavisi 51  
Multiple myeloma/Multipl myelom 51